Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden. Use of causal modeling to uncover cell-cell communication dynamics in the tumor ...
US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational programmed cell ...
In the fight against disease, programmed cell death – also known as apoptosis – is a key protective function of the body. It breaks down cells that are damaged or have undergone dangerous changes.
AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours: North Chicago, Illinois Tuesday, January 13, 2026, 14:00 Hrs ...
Aligos Therapeutics Inc. has identified programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results